SOIC Book Reviews: Dhandho Investor in the Indian Context ๐Ÿ‡ฎ๐Ÿ‡ณ๐Ÿ‡ฎ๐Ÿ‡ณ

Link to the video ๐Ÿ”—:
Scenarios that often lead to a depressed stock price, Low risk and high uncertainty where often deep value opportunities are available ๐Ÿšช
Before investing you should ask these questions to yourself otherwise you might enter the Chakravyuh but won't be able to exit like Abhimanyu. Both power of focus and circle of competence are key learnings from this episode ๐Ÿน
The type of business you enter is far more important. Eg:

Real estate NBFCs=100 foot hurdles

FMCG/Platforms/CDMOs=1 foot hurdles
Have the focus of the magnifying glass that burns the paper. Once you are on the path, stay focused, ignore the noise coming from people who haven't read the business. Yet will have an opinion because they are sitting idle on Twitter or that's how the psyche is๐ŸŽฏ
SOIC Dhandho Framework!โญ•๏ธโญ•๏ธ

โ€ข โ€ข โ€ข

Missing some Tweet in this thread? You can try to force a refresh
ใ€€

Keep Current with Intrinsic Compounding

Intrinsic Compounding Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @soicfinance

30 May
SOIC Industry Analysis|Saregama&The Music Industry. Internet beneficiaries?๐ŸŽต

Link to the video๐Ÿ”—:
How the value chain for Film Music looks like:
How the value chain for Non-Film music looks like:
Read 4 tweets
28 May
Markets reward businesses that display the ability to diversify into adjacencies while at the same time maintaining their return ratios.Signals expanding size of opportunity and managements ability to identify more profit pools

Time for a thread with examples ๐Ÿงต
Astralpoly๐Ÿšฐ isn't just a pipes company anymore. It is a water solutions provider dealing in Adhesives, Tanks, Valves, and Pipes. Homework for everyone: check the CFO compounding of the last decade
Divis Labs๐Ÿ’Š-again another API Champion which is entering Contrast Media API's which a very concentrated segment. They believe they have the process chemistry advantage over here as well!
Read 8 tweets
27 May
In the business world, the rearview mirror is always clearer than the windshield. Be forward-looking as an investor. Read everything about the industry, peers, new products, new methods of distribution, etc.

My go-to resources๐Ÿ“๐Ÿ“

1)Concalls
2)DRHPs
3)QIP docs
4)Annual Reports
5)Magazines like contract pharma, chemical weekly, Forbes, Outlook Business, etc

6)Better to know as much before you are investing. Only annual reports won't cut in today's investing world due to the increasing amount of change that is taking place

7)Read about international
players as much as possible. Looking at what has happened in the international industry can you give you some insight what can happen in the Indian industry :)

The key to it all is consistency- just read for 90mins a day for the next 3 years. The only way to get ahead is reading
Read 6 tweets
3 Nov 20
Some Questions on Laurus (I totally respect everyone else's view, these are just mine, not arguing but engaging in civilized debate like humans used to do)
Watson: Laurus has been using aggressive accounting policies and in the H1FY21 bunching of inventories has led to CFO/EBITDA deteriorating

Sherlock: Such a question was expected from you, Watson! (mockingly) Let's take a longer time horizon and check the CFO/PAT & CFO/EBITDA
CFO/EBITDA for the past years

2016: 55%
2017: 75%
2018: 77%
2019: 80%
2020: 61%

in the first half of 2020, this has fallen to somewhere around 50%. A bystander would consider this to be a red flag, however in growing companies (whenever the growth is rapid and especially
Read 19 tweets
31 Oct 20
Suven Pharmaceuticals Concall Updates:

Suven Pharma Concall Updates Q2FY21

I attended it live, there could be a mistake or two

Comparison of our business should be done yearly and not quarterly as we have said before (Due to lumpiness)
Growth guidance of 15-20% remains intact, expecting H2FY21 to be much stronger.

Product mix has also led to a decline in margins also environment-related costs have gone up.

Categorically denied the rumours of selling the business, stated that such news was there 9 months ago
and 1 year ago as well. No plans to sell.
Read 15 tweets
30 Oct 20
Pi Industries Concall Update *Q2 FY20*

Industries Q2FY21 Concall

I will be dividing this concall into 3 parts: Business, Risk and Management

Business

Both the existing molecules and the recently commercialized molecules have seen a good uptick.

More than 10 products in the
R&D pipeline in pharma. Commentary of Global Agri Innovators has shown robust strength.

Domestic Business improved by 33% and the export business grew by 25%. Topline grew by 28%.ISAGRO forms 11% of the consolidated topline.
Utilization levels are heading back to Pre-covid levels. Going forward, focusing more to improve the asset utilization levels.

EBITDA margins expanded by 293 bps due to better product mix and operating leverage. Capex done till H1FY21 is 116 crores, target for the entire year
Read 17 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(